The TOPaz Study

This study aims to investigate if a two year spell of treatment with a drug call Teriparatide, followed by one dose of treatment called Zoledronic Acid can reduce the risk of broken bones (fractures) in Osteogenesis Imperfecta (brittle bone disease). We are comparing this treatment with the usual treatment that patients with OI normally receive.

Type of Study

Phase III/IV

Study Status

Open Recruiting

Sponsor

University of Edinburgh

Principal Investigator

Dr Rachel Crowley

Contact

laura.feeney@ucd.ie